Associazione Italiana Arbitri

Evidencing AI Literacy Measures: An Operational Model for Article 4 of the EU AI Act

Article 4 of Regulation (EU) 2024/1689 was replaced on 27 July 2026 by Regulation (EU) 2026/1744. Providers and deployers must now “take measures to support the development of AI literacy” of their staff and of others dealing with AI systems on their behalf; the obligation expres...

Evidencing AI Literacy Measures: An Operational Model for Article 4 of the EU AI Act

Article 4 of Regulation (EU) 2024/1689 was replaced on 27 July 2026 by Regulation (EU) 2026/1744. Providers and deployers must now “take measures to support the development of AI literacy” of their staff and of others dealing with AI systems on their behalf; the obligation expres...

When Words Become Obligations: Terminology, Contracts and Compliance in Artificial Intelligence

European artificial intelligence governance is administered largely through words. Obligations attach to defined roles, evidence is assembled in documents, and claims travel through contracts and procurement files long after the conversation that produced them has ended. This res...

When Words Become Obligations: Terminology, Contracts and Compliance in Artificial Intelligence

European artificial intelligence governance is administered largely through words. Obligations attach to defined roles, evidence is assembled in documents, and claims travel through contracts and procurement files long after the conversation that produced them has ended. This res...

Knowing enough: On the limits of knowing the patient in epilepsy care

This contribution is theoretical in nature and does not involve the generation or analysis of new data.

Improving interpretability and applicability of welfare management decisions in dairy cows through explainable artificial intelligence

Abstract Background Improving animal welfare and health is a key objective in modern dairy systems. However, translating routinely available dairy herd improvement records into transparent and actionable welfare-related decisions remains challenging, particularly when using compl...

Milvexian with Antiplatelet Therapy after Acute Coronary Syndrome Event

BackgroundPatients are at increased risk for recurrent ischemic events after an acute coronary syndrome event. Milvexian, an oral factor XIa inhibitor, may reduce the risk of major adverse clinical events with minimal bleeding risk. MethodsIn this phase 3, randomized, placebo-con...

Patient perspectives from the BEYOND Delphi panel: burden of remaining symptoms and their fluctuations, despite treatment, in patients with generalised myasthenia gravis

Abstract Background Patients with generalised myasthenia gravis (gMG) can experience remaining symptoms despite treatment. Our study aimed to describe how remaining symptoms and their fluctuations may affect a person’s daily life while living with gMG. Methods A modified-Delphi p...